



The Top 50 Healthcare Technology CEOs of 2024

January 7, 2025

The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology CEOs of 2024. This year's list features individuals whose leadership has been a driving force behind some of the most significant advancements in healthcare. These CEOs have inspired their teams to push boundaries, fostering cultures of innovation that have led to transformative breakthroughs in medical devices, digital health, software, biotechnology, and beyond.

Their ability to lead through change, inspire their organizations, and innovate in the face of healthcare's most pressing challenges has positioned their companies as leaders in the field, driving progress to improve patient care and global health.

Among this year's awardees, Steve Chapman, CEO of Natera, is recognized for his leadership in genetic testing, overseeing the launch of 20 transformative products in oncology, women's health, and organ health, including the Signatera oncology test and the Prospera transplant assessment test. Thomas Sandgaard, CEO of Zynex Medical, is celebrated for his work in medical technology, leading the company's growth in pain management and rehabilitation through solutions like wearable electrotherapy devices that help improve patient outcomes. Randall Lipps, CEO of Omnicell, stands out for his expertise in pharmacy care, revolutionizing medication management with solutions that enhance operational efficiency, support compliance, and reduce costs across health systems globally.

This year's awardees were selected through a methodical nomination process and careful consideration of each candidate's career track record and industry contributions. Please join us in celebrating The Top 50 Healthcare Technology CEOs of 2024.

See the full list: <https://thehealthcaretechnologyreport.com/the-top-50-healthcare-technology-ceos-of-2024/>



18. Matthew Hill

Firm: Elegen

Title: Founder and Chief Executive Officer

Matt Hill, PhD, is the Founder and Chief Executive Officer of Elegen, a privately-held company based in the San Francisco Bay Area, focused on accelerating genetic medicine and synthetic biology workflows through innovative cell-free DNA manufacturing technology.

Hill's career began at Monsanto and progressed through leadership positions, culminating in his role as VP of R&D at Natera, where he co-invented the company's core technology, contributed to its successful IPO in 2015, and led the commercialization of several prenatal diagnostic products and liquid biopsy oncology tests. With over 13 peer-reviewed scientific publications and nearly two dozen patents and applications, Hill brings extensive experience in innovation across the healthcare continuum.

Frustrated by delays in obtaining custom DNA for discovery workflows, Hill founded Elegen in 2017 with a vision to eliminate DNA bottlenecks. Combining commercial experience and scientific expertise, he innovated every step of the DNA-building process to manufacture long, high-accuracy, complex DNA more quickly.

Under Hill's leadership, Elegen completed a Series A financing round in 2021 to scale its disruptive technology. In 2023, the company launched ENFINIA DNA, offering industry-leading length, NGS-verified accuracy, and speed to accelerate discovery workflows in the biopharma, agbio, and synbio industries.

In 2024, Elegen raised a \$35 million Series B funding round and released a product enhancement for manufacturing high-complexity DNA, including sequences previously rejected by other providers. In addition, Elegen secured a \$35 million collaboration with GSK to support the development of mRNA-based vaccines and genetic medicines.